I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes, with its long-term complications and comorbid conditions associated with it, is a major health hazard. The goal of treatment of diabetes is the prevention of onset and progression of complications. Therapeutic intervention to achieve this goal consists mainly of maintaining good glycemic control.\[[@ref1]\] Alpha-glucosidase inhibitors (AGIs) are widely used especially in Asian countries as a treatment option for type 2 diabetes (T2DM) patients with high postprandial glycemia (PPG).\[[@ref2]\] Among Asia, the growing burden of T2DM is a serious concern for India due to its growing population and Westernized life style environment.\[[@ref3]\] In order to examine the real life effectiveness of an AGI, acarbose, we conducted a prospective observational noninterventional study.\[[@ref4]\] The India sub-analysis data was extracted from pooled analysis of 10 large international non-interventional study/post-marketing studies.

A[IMS AND]{.smallcaps} O[BJECTIVES]{.smallcaps} {#sec1-2}
===============================================

This subanalysis of Indian patients from the international, large-scale, observational study (GlucoVIP; diabetes treatment by Glucobay® with a special therapeutic View to chosen patient groups \[4\]) investigated the effectiveness, and tolerability of acarbose as add-on or monotherapy in a range of patients regardless of age, race, sex, or severity of diabetes.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-3}
=================================================

In this abstract, we report the results of Indian subgroup which was a part of a prospective, noninterventional, noncontrolled, multicenter, multinational, observational study designed to explore the effectiveness of acarbose in a large sample of patients with T2DM under daily-life treatment conditions. Adults with pretreated or untreated T2DM prescribed acarbose as add-on or monotherapy were eligible. Two-hour postprandial blood glucose (2-hour PPG), glycosylated hemoglobin (HbA1c), and fasting blood glucose (FBG) were measured over a 3-month observation period.

R[ESULTS]{.smallcaps} {#sec1-4}
=====================

Among 15,034 patients valid for the efficacy analysis (mean age was 57.6 years and 92.6% of patients were Asian), 1996 were from India. The mean (SD) age of the patients was 50.1 (10.7) years and the mean (SD) body mass index (BMI) was 27.2 (4.4) kg/m^2^. A total of 26.5% of patients were newly diagnosed and 71.9% of patients had previous diagnosis of diabetes. Also, 73.4% of patients had specific concomitant diseases. Majority of them were diagnosed with other diabetic complications (21.9%) followed by vascular disease + CHF (16.2%).

Mean (SD) 2-hour PPG decreased from 241.8 (68.3) mg/dl at initial visit to 170.2 (46.5) mg/dl at final visit (after 12.8 \[4.1\] weeks) in total population, and from 243.9 (64.0) mg/dL at initial visit to 169.5 (40.2) mg/dL at final visit (after 12.5 \[2.9\] weeks) in an Indian subpopulation \[[Figure 1](#F1){ref-type="fig"}\].
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Mean HbA1c decreased from 8.2% (1.6) at initial visit to 7.2% (1.1) in the total population, and from 8.4% (1.3) to 7.4% (0.8) in Indian, mean FBG decreased from 157.4 (49.2) mg/dL to 124.8 (30.5) mg/dL in total population and from 158.3 (45.1) mg/dL to 120.4 (30.1) mg/dL in Indian, and mean body weight (BW) decreased from 70.4 (13.4) kg to 69.5 (12.8) mg/dL in total population and from 72.7 (12.6) kg to 71.3 (12.2) kg in the Indian subgroup.

The efficacy of acarbose was rated 'very good' or 'good' in 85.5% of patients in total population and 91.1% in Indian population, and tolerability as very good' or 'good' in 84.9% of patients in the total population and 88.0% in the Indian population \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\].
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D[ISCUSSION]{.smallcaps} {#sec1-5}
========================

This is the first study to report data about efficacy of acarbose in large number of T2DM patients across India. The results demonstrated that acarbose was effective in reducing all glycemic parameters measured, and these improvements were observed by the first follow-up visit, after a mean of only 4.9 weeks. Overall, 2-hour PPG decreased in 94.4% of patients, HbA1c decreased in 52.4% of patients and FBG decreased in 90.6% of patients. These results clearly show that acarbose was extremely effective in reducing PPG over a short time period. The International Diabetes Federation (IDF) 2011 guidelines\[[@ref5]\] recommend control of PPG (1-2 hours after a meal) in order to reduce vascular events. Reducing PPG is also important because it significantly contributes to HbA1c in the nearly well-controlled patients.\[[@ref5][@ref6]\] Our results indicate that HbA1c was reduced by ≥1% over a 3-month period, which may reflect the significant improvement in PPG. The mean weight reduction of 1.4 kg observed during this study was similar to reductions observed in other large surveillance studies.

The safety data were not analyzed in the current pooled data analysis; however the results from the present study were consistent with the known safety profile of acarbose.\[[@ref4]\]

The results of this study show that acarbose is effective and well tolerated in a population of Indian patients with diabetes. Epidemiological studies have shown that complications such as cardiovascular disease, cerebrovascular disease, and diabetic complications are common in populations from India;\[[@ref7]\] our study clearly indicates that acarbose is effective in patients from Asian countries with a range of vascular comorbidities.

C[ONCLUSION]{.smallcaps} {#sec1-6}
========================

The results of this observational study support the notion that acarbose is effective, safe and, well tolerated in Indian patients with T2DM to the same extent as in the larger international cohort of patients.
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